{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:47:48Z","timestamp":1791978468453,"version":"4.4.0"},"reference-count":30,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T00:00:00Z","timestamp":1689897600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Chongqing Science and Health joint project","award":["2023MSXM055 and 2020MSXM041"],"award-info":[{"award-number":["2023MSXM055 and 2020MSXM041"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Expression levels of transmembrane protein 41A (<jats:italic>TMEM41A)<\/jats:italic> are related to the progression of malignant tumors. However, the association between <jats:italic>TMEM41A<\/jats:italic> expression and endometrial carcinoma (EC) remains unclear. This study aims to identify the roles of <jats:italic>TMEM41A<\/jats:italic> expression in the prognosis of patients with EC and its correlation with EC progression.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>The <jats:italic>TMEM41A<\/jats:italic> expression and its correlation with the survival of patients with EC were assessed. Cox regression analysis was used to identify the prognostic factors, while nomograms were used to examine the association between the prognostic factors and the survival of patients with EC. Finally, the link between <jats:italic>TMEM41A<\/jats:italic> level and immune microenvironment and RNA modifications was investigated in EC.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p><jats:italic>TMEM41A<\/jats:italic> was overexpressed in EC. <jats:italic>TMEM41A<\/jats:italic> overexpression could diagnose the EC and evaluate the poor prognosis of patients. Overexpression of <jats:italic>TMEM41A<\/jats:italic> was associated with clinical stage, age, weight, histological subtype, tumor grade, and survival status of patients with EC. Clinical stage, age, tumor grade, radiotherapy, and <jats:italic>TMEM41A<\/jats:italic> overexpression were factors of poor prognosis in patients with EC. The nomograms revealed the correlation between the <jats:italic>TMEM41A<\/jats:italic> level and survival time of patients with EC at 1, 3, and 5 years. Furthermore, <jats:italic>TMEM41A<\/jats:italic> overexpression was significantly correlated with the level of the stromal score, immune score, estimate score, NK CD56 bright cells, iDC, NK cells, eosinophils, pDC, T cells, TReg, cytotoxic cells, mast cells, Th17 cells, neutrophils, aDC, NK CD56 dim cells, TFH, Th2 cells, CD8 T cells, macrophages, immune cell markers, and RNA modifications.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p><jats:italic>TMEM41A<\/jats:italic> is overexpressed in EC tissues and is associated with the prognosis, immune microenvironment, and RNA modification. Our preliminary studies indicate that overexpression of <jats:italic>TMEM41A<\/jats:italic> can potentially serve as a biomarker for EC treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0285817","type":"journal-article","created":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T17:29:34Z","timestamp":1689960574000},"page":"e0285817","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":5,"title":["TMEM41A overexpression correlates with poor prognosis and immune alterations in patients with endometrial carcinoma"],"prefix":"10.1371","volume":"18","author":[{"given":"Ke","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Li","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Qiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Tong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4941-3879","authenticated-orcid":true,"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,7,21]]},"reference":[{"key":"pone.0285817.ref001","doi-asserted-by":"crossref","first-page":"2334338","DOI":"10.1155\/2022\/2334338","article-title":"ATAD2 Upregulation Promotes Tumor Growth and Angiogenesis in Endometrial Cancer and Is Associated with Its Immune Infiltration","volume":"2022","author":"C Wang","year":"2022","journal-title":"Dis Markers"},{"key":"pone.0285817.ref002","doi-asserted-by":"crossref","first-page":"6235771","DOI":"10.1155\/2022\/6235771","article-title":"TRIM44 Promotes Endometrial Carcinoma Progression by Activating the FRS2 Signalling Pathway.","volume":"2022","author":"Y Song","year":"2022","journal-title":"Evid Based Complement Alternat Med"},{"key":"pone.0285817.ref003","doi-asserted-by":"crossref","first-page":"102973","DOI":"10.1016\/j.critrevonc.2020.102973","article-title":"PARP and PD-1\/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer","volume":"152","author":"CCB Post","year":"2020","journal-title":"Crit Rev Oncol Hematol"},{"key":"pone.0285817.ref004","doi-asserted-by":"crossref","first-page":"918140","DOI":"10.3389\/fimmu.2022.918140","article-title":"The m6A\/m5C\/m1A Regulated Gene Signature Predicts the Prognosis and Correlates With the Immune Status of Hepatocellular Carcinoma","volume":"13","author":"D Li","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"pone.0285817.ref005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12263-022-00705-y","article-title":"Programmed death-ligand 1 signaling and expression are reversible by lycopene via PI3K\/AKT and Raf\/MEK\/ERK pathways in tongue squamous cell carcinoma","volume":"17","author":"M Peng","year":"2022","journal-title":"Genes Nutr"},{"key":"pone.0285817.ref006","article-title":"Chromosome 12 Open Reading Frame 49 Promotes Tumor Growth and Predicts Poor Prognosis in Colorectal Cancer","author":"Y Tao","year":"2022","journal-title":"Dig Dis Sci"},{"issue":"3","key":"pone.0285817.ref007","first-page":"2963","article-title":"Expression of transmembrane protein 41A is associated with metastasis via the modulation of E\u2011cadherin in radically resected gastric cancer","volume":"18","author":"B Lin","year":"2018","journal-title":"Mol Med Rep"},{"key":"pone.0285817.ref008","first-page":"4022896","article-title":"The Risk Model Based on the Three Oxidative Stress-Related Genes Evaluates the Prognosis of LAC Patients.","volume":"2022","author":"Q Guo","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"1","key":"pone.0285817.ref009","doi-asserted-by":"crossref","first-page":"21530","DOI":"10.1038\/s41598-020-78560-3","article-title":"Pan-cancer analysis of genomic properties and clinical outcome associated with tumor tertiary lymphoid structure","volume":"10","author":"Z Lin","year":"2020","journal-title":"Sci Rep"},{"key":"pone.0285817.ref010","doi-asserted-by":"crossref","first-page":"990247","DOI":"10.3389\/fonc.2022.990247","article-title":"SLC25A25-AS1 over-expression could be predicted the dismal prognosis and was related to the immune microenvironment in prostate cancer","volume":"12","author":"YY Zhao","year":"2022","journal-title":"Front Oncol"},{"key":"pone.0285817.ref011","doi-asserted-by":"crossref","first-page":"102609","DOI":"10.1016\/j.ebiom.2019.102609","article-title":"MELK promotes Endometrial carcinoma progression via activating mTOR signaling pathway.","volume":"51","author":"Q Xu","year":"2020","journal-title":"EBioMedicine"},{"key":"pone.0285817.ref012","doi-asserted-by":"crossref","first-page":"986447","DOI":"10.3389\/fimmu.2022.986447","article-title":"Downregulation of T-cell cytotoxic marker IL18R1 promotes cancer proliferation and migration and is associated with dismal prognosis and immunity in lung squamous cell carcinoma","volume":"13","author":"Q Guo","year":"2022","journal-title":"Front Immunol"},{"key":"pone.0285817.ref013","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s12935-020-01591-3","article-title":"BTG1 inhibits malignancy as a novel prognosis signature in endometrial carcinoma","volume":"20","author":"Y Li","year":"2020","journal-title":"Cancer Cell Int"},{"key":"pone.0285817.ref014","doi-asserted-by":"crossref","first-page":"947054","DOI":"10.3389\/fonc.2022.947054","article-title":"Pan-cancer analysis reveals DDX21 as a potential biomarker for the prognosis of multiple tumor types.","volume":"12","author":"A Hu","year":"2022","journal-title":"Front Oncol"},{"issue":"2","key":"pone.0285817.ref015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/cbin.11950","article-title":"OTUB2 promotes the progression of endometrial cancer by regulating the PKM2-mediated PI3K\/AKT signaling pathway","volume":"47","author":"Q Zhang","year":"2023","journal-title":"Cell Biol Int"},{"key":"pone.0285817.ref016","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.2147\/CMAR.S290467","article-title":"USP5 Promotes Uterine Corpus Endometrial Carcinoma Cell Growth and Migration via mTOR\/4EBP1 Activation.","volume":"13","author":"Y Li","year":"2021","journal-title":"Cancer Manag Res."},{"issue":"6","key":"pone.0285817.ref017","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.3390\/jcm12062241","article-title":"Recent Advances in Endometrial Cancer Management.","volume":"12","author":"V Di Donato","year":"2023","journal-title":"J Clin Med"},{"issue":"7","key":"pone.0285817.ref018","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/cac2.12067","article-title":"A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: A population-based analysis","volume":"40","author":"J Wu","year":"2020","journal-title":"Cancer Commun (Lond)."},{"issue":"1","key":"pone.0285817.ref019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1186\/s12885-021-08466-4","article-title":"A nomogram prediction model for lymph node metastasis in endometrial cancer patients","volume":"21","author":"Z Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"pone.0285817.ref020","article-title":"A nomogram for predicting overall survival in patients with endometrial carcinoma: A SEER-based study.","author":"R Li","year":"2022","journal-title":"Int J Gynaecol Obstet."},{"issue":"6","key":"pone.0285817.ref021","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors.","volume":"18","author":"DB Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"pone.0285817.ref022","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial","volume":"326","author":"H Luo","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"pone.0285817.ref023","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"HA Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"pone.0285817.ref024","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41374-021-00543-3","article-title":"N-methyladenosine reader YTHDF2-mediated long noncoding RNA FENDRR degradation promotes cell proliferation in endometrioid endometrial carcinoma","volume":"101","author":"J Shen","year":"2021","journal-title":"Lab Invest"},{"issue":"6","key":"pone.0285817.ref025","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/cbin.11570","article-title":"WTAP facilitates progression of endometrial cancer via CAV-1\/NF-\u03baB axis","volume":"45","author":"Q Li","year":"2021","journal-title":"Cell Biol Int"},{"issue":"3","key":"pone.0285817.ref026","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.7150\/thno.49345","article-title":"IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression","volume":"11","author":"L Zhang","year":"2021","journal-title":"Theranostics"},{"issue":"9","key":"pone.0285817.ref027","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1080\/15476286.2020.1841458","article-title":"FTO demethylates m6A modifications in HOXB13 mRNA and promotes endometrial cancer metastasis by activating the WNT signalling pathway","volume":"18","author":"L Zhang","year":"2021","journal-title":"RNA Biol"},{"issue":"4","key":"pone.0285817.ref028","doi-asserted-by":"crossref","first-page":"571","DOI":"10.3390\/healthcare11040571","article-title":"Role of Genomic and Molecular Biology in the Modulation of the Treatment of Endometrial Cancer: Narrative Review and Perspectives.","volume":"11","author":"I Cuccu","year":"2023","journal-title":"Healthcare (Basel)."},{"issue":"3","key":"pone.0285817.ref029","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3390\/biom13030499","article-title":"Novel Insights into Molecular Mechanisms of Endometrial Diseases.","volume":"13","author":"T Golia D\u2019Aug\u00e8","year":"2023","journal-title":"Biomolecules"},{"issue":"12","key":"pone.0285817.ref030","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.3390\/healthcare10122464","article-title":"Radiomics and Molecular Classification in Endometrial Cancer (The ROME Study): A Step Forward to a Simplified Precision Medicine.","volume":"10","author":"G Bogani","year":"2022","journal-title":"Healthcare (Basel)."}],"updated-by":[{"DOI":"10.1371\/journal.pone.0348229","type":"expression_of_concern","label":"Expression of concern","source":"publisher","updated":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T00:00:00Z","timestamp":1777420800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,21]],"date-time":"2023-07-21T17:30:03Z","timestamp":1689960603000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0285817"}},"subtitle":[],"editor":[{"given":"Andrea","family":"Giannini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,7,21]]},"references-count":30,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0285817","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,21]]}}}